T
Tatsuya Maruyama
Researcher at Keio University
Publications - 3
Citations - 1150
Tatsuya Maruyama is an academic researcher from Keio University. The author has contributed to research in topics: Eritoran & Pharmacodynamics. The author has an hindex of 3, co-authored 3 publications receiving 1085 citations.
Papers
More filters
Journal ArticleDOI
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
Steven M. Opal,Pierre-François Laterre,Bruno François,Steven P. LaRosa,Derek C. Angus,Jean-Paul Mira,Xavier Wittebole,Thierry Dugernier,Dominique Perrotin,Mark Tidswell,Luis Jauregui,Kenneth Krell,Jan Pachl,Takahashi Takeshi,Claus Peckelsen,Edward Cordasco,Chia-Sheng Chang,Sandra Oeyen,Naoki Aikawa,Tatsuya Maruyama,Roland M. H. Schein,Andre C. Kalil,Marc Van Nuffelen,Melvyn Lynn,Daniel P. Rossignol,Jagadish Gogate,Mary B. Roberts,Mary B. Roberts,Janice L. Wheeler,Jean Louis Vincent +29 more
TL;DR: Among patients with severe sepsis, the use of eritoran, compared with placebo, did not result in reduced 28-day mortality, and no significant differences were observed in any of the prespecified subgroups.
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis
Steven M. Opal,Pierre-François Laterre,Bruno François,Steven P. LaRosa,Derek C. Angus,Jean-Paul Mira,Xavier Wittebole,Thierry Dugernier,Dominique Perrotin,Mark Tidswell,Luis Jauregui,Kenneth Krell,Jan Pachl,Takahashi Takeshi,Claus Peckelsen,Edward Cordasco,Chia-Sheng Chang,Sandra Oeyen,Naoki Aikawa,Tatsuya Maruyama,Roland M. H. Schein,Andre C. Kalil,Marc Van Nuffelen,Melvyn Lynn,Daniel P. Rossignol +24 more
TL;DR: Steven M. Opal, MDPierre-Francois Laterre, MDBruno Francois, MDSteven P. LaRosa, MDDerek C. Kalil, MD, MPHMarc Van Nuffelen, MDMelvyn Lynn, PhDDaniel P. Rossignol, PhDJogadish Gogate, PhDMary B. Roberts, MSJanice L. Wheeler, BS, RNJean-Louis Vincent, MD as discussed by the authors
Journal ArticleDOI
A Phase II study of polyclonal anti-TNF-α (AZD9773) in Japanese patients with severe sepsis and/or septic shock
Naoki Aikawa,Takahashi Takeshi,Satoshi Fujimi,Takeshi Yokoyama,Katsunori Yoshihara,Toshiaki Ikeda,Daikai Sadamitsu,Michiru Momozawa,Tatsuya Maruyama +8 more
TL;DR: AZD9773 was generally well tolerated with dose-proportional pharmacokinetics in Japanese patients with severe sepsis/septic shock and a similar pattern of response was observed with interleukin-6 (IL-6) and IL-8.